Opus Genetics announced that its gene therapy candidate OPGx-LCA5 for Leber congenital amaurosis type 5 (LCA5), a rare inherited retinal disease causing early blindness, has been accepted into the FDA's Rare Disease Evidence Principles (RDEP) program. This acceptance supports early collaboration with the FDA on regulatory strategy and clinical trial design, aiming to streamline development and approval for this ultra-rare condition with no current treatments. OPGx-LCA5 is in Phase 1/2 trials showing promising vision improvements and has multiple FDA designations including RMAT. The company will work closely with the FDA to advance the therapy toward potential approval.
A three-day online training on Pharmaceutical Regulatory Affairs in Asia is scheduled for October 20-22, 2026, aiming to help professionals understand diverse regulatory requirements across major Asian markets including China, India, Korea, and ASEAN...
The global workwear market, valued at $265.12 billion in 2025, is expected to grow to $344.71 billion by 2031 with a 4.5% CAGR. Growth is fueled by rising corporate employment worldwide, especially in Asia-Pacific, and increased focus on professional...
The global microalgae-based aquafeed market is projected to grow from $320 million in 2026 to $481 million by 2031, at an 8.5% CAGR. Key growth drivers include rapid cost reductions in closed photobioreactor farming, making algae competitive with fis...
The global consumer finance market is projected to expand from $9.87 trillion in 2025 to $14.08 trillion by 2031, growing at a 6.17% CAGR. Key growth drivers include embedded finance at point-of-sale, which boosts credit uptake by integrating lending...
Xcel Brands has signed a licensing agreement with KBL Group to produce ready-to-wear collections for OFF/DUTY by Coco Rocha, a fashion brand created with supermodel Coco Rocha. KBL Group will handle sourcing, product development, manufacturing, and s...
